PHASE II STUDY OF IMATINIB MESYLATE AS THERAPY FOR PATIENTS WITH SYSTEMIC MASTOCYTOSIS

Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003–2005 in phase II clinical trial with ima...

Full description

Saved in:
Bibliographic Details
Main Authors: Vega-Ruiz, Arturo, Cortes, Jorge E., Sever, Matjaz, Manshouri, Taghi, Quintás-Cardama, Alfonso, Luthra, Raja, Kantarjian, Hagop M., Verstovsek, Srdan
Format: Artigo
Language:Inglês
Published: 2009
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184059/
https://ncbi.nlm.nih.gov/pubmed/19193436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2008.12.020
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items